Literature DB >> 15711037

Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation.

P H J van der Voort1, R T Gerritsen, M A Kuiper, P H M Egbers, W P Kingma, E C Boerma.   

Abstract

BACKGROUND/AIMS: To study the effect of different modes of continuous veno-venous haemofiltration (CVVH) on filter run time (FRT).
METHODS: We studied, in two consecutive prospective, randomised and crossover studies, 16 and 15 patients with acute renal failure during critical illness. Study A compared pre- versus post-dilution, and study B compared regional anticoagulation with heparin (pre-filter) and protamine (post-filter) (HP) versus nadroparin (NP) pre-filter. All CVVH sessions were standardised. Analyses were by Wilcoxon rank sum tests.
RESULTS: Study A: During pre-dilution the median FRT was 45.7 vs. 16.1 h in post-dilution CVVH (p = 0.005). The median creatinine clearance during pre-dilution was 33 vs. 45 ml/min in post-dilution (p = 0.001). Study B: During NP, median FRT was 39.5 vs. 12.3 h during HP CVVH (p = 0.045).
CONCLUSIONS: Pre-dilution CVVH results in the greatest FRT but a lower plasma creatinine clearance compared to post-dilution. Regional anticoagulation with heparin-protamine resulted in a significantly shorter FRT compared to systemic NP anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711037     DOI: 10.1159/000083938

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  14 in total

Review 1.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

Review 2.  Controversies in paediatric continuous renal replacement therapy.

Authors:  Graeme Maclaren; Warwick Butt
Journal:  Intensive Care Med       Date:  2009-01-31       Impact factor: 17.440

3.  Revisiting Filtration Fraction as an Index of the Risk of Hemofilter Clotting in Continuous Venovenous Hemofiltration.

Authors:  Parta Hatamizadeh; Ashita Tolwani; Paul Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2020-05-13       Impact factor: 8.237

Review 4.  Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.

Authors:  Yasushi Tsujimoto; Sho Miki; Hiroki Shimada; Hiraku Tsujimoto; Hideto Yasuda; Yuki Kataoka; Tomoko Fujii
Journal:  Cochrane Database Syst Rev       Date:  2021-09-14

5.  Anticoagulation in patients with acute kidney injury undergoing kidney replacement therapy.

Authors:  Rupesh Raina; Ronith Chakraborty; Andrew Davenport; Patrick Brophy; Sidharth Sethi; Mignon McCulloch; Timothy Bunchman; Hui Kim Yap
Journal:  Pediatr Nephrol       Date:  2021-10-19       Impact factor: 3.651

6.  Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.

Authors:  Hiraku Tsujimoto; Yasushi Tsujimoto; Yukihiko Nakata; Tomoko Fujii; Sei Takahashi; Mai Akazawa; Yuki Kataoka
Journal:  Cochrane Database Syst Rev       Date:  2020-03-13

7.  Timing of renal replacement therapy initiation for acute kidney injury.

Authors:  Alicia Isabel I Fayad; Daniel G Buamscha; Agustín Ciapponi
Journal:  Cochrane Database Syst Rev       Date:  2018-12-18

8.  Role of citrate and other methods of anticoagulation in patients with severe liver failure requiring continuous renal replacement therapy.

Authors:  Josée Bouchard; François Madore
Journal:  NDT Plus       Date:  2008-12-09

9.  Circuit life span in critically ill children on continuous renal replacement treatment: a prospective observational evaluation study.

Authors:  Jimena del Castillo; Jesús López-Herce; Elena Cidoncha; Javier Urbano; Santiago Mencía; Maria J Santiago; Jose M Bellón
Journal:  Crit Care       Date:  2008-07-25       Impact factor: 9.097

Review 10.  Clinical review: Patency of the circuit in continuous renal replacement therapy.

Authors:  Michael Joannidis; Heleen M Oudemans-van Straaten
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.